Clinical trials

Lu AE58054 Lundbeck Starbright Study 
To establish efficacy of Lu AE58054 as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Principal Investigator: Bryan M. Spann, DO, PhD
IRB Number: 2 Number: NCT02006641
Status: Open for enrollment

The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories, physical examinations, ECGs and solicitation of adverse events. To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric Inventory (NPI) and Mini-mental State Examination (MMSE).

Principal Investigator: Joseph C. Masdeu, MD, PhD
IRB Number: IRB0414-0081 Number: NCT02079909
Status: Close to enrollment

A4: Drug study for individuals with a strong family history of Alzheimer’s that asymptomatic
Statuts: Not Open for Enrollment Yet

A16: Autopsy study for Alzheimer’s  
Status: Not Open for Enrollment Yet

For more information

Clinical Research Coordinator:
Jennifer Garrett, RN
Phone: 713.441.9484